STOCK TITAN

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

Welcome to our dedicated news page for Apellis Pharmaceuticals (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apellis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apellis Pharmaceuticals's position in the market.

Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reported total revenues of $110.4 million in the third quarter of 2023. SYFOVRE® generated $75.3 million in revenue, while EMPAVELI® generated $23.9 million. The company completed a corporate restructuring to drive growth and improve operational efficiencies. Positive top-line data from the Phase 2 NOBLE study investigating pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G will be presented at Kidney Week. Cash and cash equivalents stood at $452 million as of September 30, 2023, providing a cash runway into at least the second quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
-
Rhea-AI Summary
Apellis Pharmaceuticals to discuss Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences earnings
-
Rhea-AI Summary
Apellis Pharmaceuticals announces positive 24-month results for SYFOVRE in treating geographic atrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
Rhea-AI Summary
Positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences clinical trial
-
Rhea-AI Summary
Apellis Pharmaceuticals grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals provides update on launch of SYFOVRE for geographic atrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
Rhea-AI Summary
Apellis Pharmaceuticals receives FDA approval for the EMPAVELI Injector, a compact on-body device for self-administration of EMPAVELI in PNH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary
Apellis Pharmaceuticals announces permanent J-code for SYFOVRE, the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Summary
Apellis Pharmaceuticals to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
Apellis Pharmaceuticals Inc

Nasdaq:APLS

APLS Rankings

APLS Stock Data

6.25B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.